ATE366769T1 - Biologisch abbaubare poly(beta-aminoester) und anwendungen davon - Google Patents

Biologisch abbaubare poly(beta-aminoester) und anwendungen davon

Info

Publication number
ATE366769T1
ATE366769T1 AT04753364T AT04753364T ATE366769T1 AT E366769 T1 ATE366769 T1 AT E366769T1 AT 04753364 T AT04753364 T AT 04753364T AT 04753364 T AT04753364 T AT 04753364T AT E366769 T1 ATE366769 T1 AT E366769T1
Authority
AT
Austria
Prior art keywords
polymers
poly
bis
preparing
prepared
Prior art date
Application number
AT04753364T
Other languages
English (en)
Inventor
Robert Langer
David Lynn
Daniel Anderson
Akin Akinc
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Application granted granted Critical
Publication of ATE366769T1 publication Critical patent/ATE366769T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/44—Polyester-amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/12—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from polycarboxylic acids and polyhydroxy compounds
    • C08G63/40—Polyesters derived from ester-forming derivatives of polycarboxylic acids or of polyhydroxy compounds, other than from esters thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/68—Polyesters containing atoms other than carbon, hydrogen and oxygen
    • C08G63/685—Polyesters containing atoms other than carbon, hydrogen and oxygen containing nitrogen
    • C08G63/6854—Polyesters containing atoms other than carbon, hydrogen and oxygen containing nitrogen derived from polycarboxylic acids and polyhydroxy compounds
    • C08G63/6856—Dicarboxylic acids and dihydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/0273—Polyamines containing heterocyclic moieties in the main chain
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/028—Polyamidoamines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • C08G73/0605—Polycondensates containing five-membered rings, not condensed with other rings, with nitrogen atoms as the only ring hetero atoms
    • C08G73/0611—Polycondensates containing five-membered rings, not condensed with other rings, with nitrogen atoms as the only ring hetero atoms with only one nitrogen atom in the ring, e.g. polypyrroles
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • C08G73/0605—Polycondensates containing five-membered rings, not condensed with other rings, with nitrogen atoms as the only ring hetero atoms
    • C08G73/0616—Polycondensates containing five-membered rings, not condensed with other rings, with nitrogen atoms as the only ring hetero atoms with only two nitrogen atoms in the ring
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
    • C08L67/02—Polyesters derived from dicarboxylic acids and dihydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
    • C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L77/00—Compositions of polyamides obtained by reactions forming a carboxylic amide link in the main chain; Compositions of derivatives of such polymers
    • C08L77/04—Polyamides derived from alpha-amino carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L79/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
    • C08L79/02—Polyamines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L89/00—Compositions of proteins; Compositions of derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L99/00—Compositions of natural macromolecular compounds or of derivatives thereof not provided for in groups C08L89/00 - C08L97/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Medical Informatics (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT04753364T 2003-05-28 2004-05-26 Biologisch abbaubare poly(beta-aminoester) und anwendungen davon ATE366769T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/446,444 US7427394B2 (en) 2000-10-10 2003-05-28 Biodegradable poly(β-amino esters) and uses thereof

Publications (1)

Publication Number Publication Date
ATE366769T1 true ATE366769T1 (de) 2007-08-15

Family

ID=33489383

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04753364T ATE366769T1 (de) 2003-05-28 2004-05-26 Biologisch abbaubare poly(beta-aminoester) und anwendungen davon
AT07013193T ATE475685T1 (de) 2003-05-28 2004-05-26 Biologisch abbaubare poly(beta-amino-)ester und verwendungen davon

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07013193T ATE475685T1 (de) 2003-05-28 2004-05-26 Biologisch abbaubare poly(beta-amino-)ester und verwendungen davon

Country Status (9)

Country Link
US (1) US7427394B2 (de)
EP (2) EP1639029B1 (de)
JP (3) JP4740864B2 (de)
AT (2) ATE366769T1 (de)
CA (1) CA2527722C (de)
DE (2) DE602004028418D1 (de)
ES (2) ES2290737T3 (de)
PT (1) PT1639029E (de)
WO (1) WO2004106411A2 (de)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080281041A1 (en) 1999-06-07 2008-11-13 Rozema David B Reversibly Masked Polymers
USRE43612E1 (en) 2000-10-10 2012-08-28 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US6998115B2 (en) 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US7223851B2 (en) * 2003-02-06 2007-05-29 General Dynamics Advanced Information Systems, Inc. Nucleic acid-binding polymers
US7309757B2 (en) 2003-06-20 2007-12-18 Agency For Science, Technology And Research Polymers for the delivery of bioactive agents and methods of their preparation
WO2005007819A2 (en) 2003-07-09 2005-01-27 Wisconsin Alumni Research Foundation Charge-dynamic polymers and delivery of anionic compounds
US7943179B2 (en) * 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
US20050123596A1 (en) * 2003-09-23 2005-06-09 Kohane Daniel S. pH-triggered microparticles
US20050215507A1 (en) * 2004-03-04 2005-09-29 Massachusetts Institute Of Technology Therapeutic anti-cancer DNA
WO2005110438A2 (en) * 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the intracellular delivery of polysaccharides
KR20050102295A (ko) * 2004-04-21 2005-10-26 학교법인 포항공과대학교 리포좀 및 그 제조방법
US7358223B2 (en) * 2004-10-04 2008-04-15 Nitto Denko Corporation Biodegradable cationic polymers
DK1842557T3 (da) 2004-12-22 2013-12-02 Nitto Denko Corp Lægemiddelbærer og lægemiddelbærerkit til inhibition af fibrose
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
KR100732013B1 (ko) * 2005-03-18 2007-06-25 성균관대학교산학협력단 ｐＨ 민감성 블록 공중합체 및 이를 이용한 고분자 마이셀
WO2006118547A1 (en) * 2005-04-29 2006-11-09 Agency For Science, Technology And Research Hyperbranched polymers and their applications
US20060257355A1 (en) * 2005-05-10 2006-11-16 Abiomed, Inc. Impregnated polymer compositions and devices using them
WO2007051303A1 (en) 2005-11-02 2007-05-10 Protiva Biotherapeutics, Inc. MODIFIED siRNA MOLECULES AND USES THEREOF
US20090317802A1 (en) * 2005-12-09 2009-12-24 Bhatia Sangeeta N Compositions and Methods to Monitor RNA Delivery to Cells
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
US7700541B2 (en) * 2006-04-06 2010-04-20 Nitto Denko Corporation Biodegradable cationic polymers
EP2032652A4 (de) * 2006-06-05 2011-08-17 Massachusetts Inst Technology Vernetzte abbaubare polymere und ihre verwendung
CN100428964C (zh) * 2006-06-29 2008-10-29 武汉理工大学 RGD多肽接枝聚(羟基乙酸-L-赖氨酸-L-乳酸)/β-磷酸三钙复合材料及其制备方法
CA2658768C (en) 2006-07-21 2016-05-17 Massachusetts Institute Of Technology End-modified poly(beta-amino esters) and uses thereof
CN101500548A (zh) * 2006-08-18 2009-08-05 弗·哈夫曼-拉罗切有限公司 用于体内递送多核苷酸的多缀合物
CA2671850A1 (en) * 2006-12-08 2008-06-19 Massachusetts Institute Of Technology Delivery of nanoparticles and/or agents to cells
KR100825519B1 (ko) * 2007-01-05 2008-04-25 주식회사 바이오폴리메드 키토산 기재 고분자 접합체 및 그 제조방법
US20100196492A1 (en) * 2007-03-08 2010-08-05 Green Jordan J Electrostatic coating of particles for drug delivery
TWI407971B (zh) 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
EP2162283B1 (de) 2007-06-14 2015-08-12 Massachusetts Institute of Technology Selbstaufbauende filme für protein- und arzneimittelabgabeanwendungen
EP2207570A2 (de) 2007-09-14 2010-07-21 Nitto Denko Corporation Arzneimittelträger
DK2214646T3 (da) 2007-10-05 2021-10-04 Univ Wayne State Dendrimers for sustained release of compounds
WO2009049100A2 (en) * 2007-10-09 2009-04-16 Wisconsin Alumni Research Foundation Ultrathin multilayered films for controlled release of anionic reagents
EP2229445B1 (de) * 2007-12-13 2012-12-05 Polyplus Transfection Mittel zur zuführung von für gen-silencing aktiven nukleinsäuren unter verwendung synthetischer polymere
AU2008342535B2 (en) 2007-12-27 2015-02-05 Arbutus Biopharma Corporation Silencing of polo-like kinase expression using interfering RNA
EP2244697A1 (de) * 2008-01-29 2010-11-03 Shire Human Genetic Therapies, Inc. Therapeutische zusammensetzungen
US20110218140A1 (en) * 2008-02-25 2011-09-08 Gonsalves Kenneth E Biodegradable therapeutic nanoparticles containing an antimicrobial agent
AU2009236219B8 (en) 2008-04-15 2015-06-25 Arbutus Biopharma Corporation Silencing of CSN5 gene expression using interfering RNA
US8324333B2 (en) * 2008-06-05 2012-12-04 Wisconsin Alumni Research Foundation Anionic charge-dynamic polymers for release of cationic agents
CN102137658A (zh) 2008-06-30 2011-07-27 斯兰斯德有限公司 局部递送药物的方法、组合物和系统
WO2010021973A2 (en) 2008-08-17 2010-02-25 Massachusetts Institute Of Technology Controlled delivery of bioactive agents from decomposable films
JP6087504B2 (ja) 2008-11-07 2017-03-01 マサチューセッツ インスティテュート オブ テクノロジー アミノアルコールリピドイドおよびその使用
KR102344392B1 (ko) * 2008-11-10 2021-12-28 알닐람 파마슈티칼스 인코포레이티드 치료제 운반용 신규 지질 및 조성물
US8163861B2 (en) * 2009-01-15 2012-04-24 Living Proof, Inc. Beta-amino ester compounds and uses thereof
CA2752682A1 (en) * 2009-02-18 2010-08-26 The Lubrizol Corporation Composition containing ester compounds and a method of lubricating an internal combustion engine
WO2010107957A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012520686A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたシグナル伝達性転写因子６（ＳＴＡＴ６）遺伝子発現のＲＮＡ干渉媒介性阻害
JP2012520683A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた結合組織増殖因子（ＣＴＧＦ）遺伝子発現のＲＮＡ干渉媒介性阻害
CN102439151A (zh) 2009-03-19 2012-05-02 默沙东公司 使用短干扰核酸（siNA）的RNA干扰介导的BTB和CNC同系物1，碱性亮氨酸拉链转录因子1（Bach1）基因表达的抑制
WO2010111464A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111471A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
SG174581A1 (en) 2009-03-27 2011-10-28 Merck Sharp & Dohme RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012521764A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた胸腺間質性リンパ球新生因子（ＴＳＬＰ）遺伝子発現のＲＮＡ干渉媒介性阻害
EP2411018A2 (de) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. Rna-interferenz-vermittelte hemmung der nervenwachstumsfaktor-betaketten (ngf9-gen-expression mittels sina (short interfering nucleic acid)
WO2010132879A2 (en) 2009-05-15 2010-11-18 The Johns Hopkins University Multicomponent degradable cationic polymers
US9717694B2 (en) 2009-05-15 2017-08-01 The Johns Hopkins University Peptide/particle delivery systems
NZ700688A (en) 2009-12-01 2016-02-26 Shire Human Genetic Therapies Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
WO2011081659A1 (en) 2009-12-15 2011-07-07 Massachusetts Institute Of Technology Degradable polymer nanostructure materials
WO2011078457A2 (ko) 2009-12-22 2011-06-30 성균관대학교산학협력단 다이온성 복합체 마이셀을 형성하는 피에이치 민감성 블록공중합체 및 이를 이용한 약물 또는 단백질 전달체
KR101291642B1 (ko) * 2010-03-03 2013-08-01 성균관대학교산학협력단 폴리(아미도 아민) 올리고머 하이드로젤 조성물 및 이를 이용한 약물전달체
EP2545100A2 (de) 2010-03-09 2013-01-16 Council of Scientific & Industrial Research Biologisch abbaubare polymerhydrogelzusammensetzung
JP2013528665A (ja) 2010-03-26 2013-07-11 メルサナ セラピューティックス， インコーポレイテッド ポリヌクレオチドの送達のための修飾ポリマー、その製造方法、およびその使用方法
EP2582387A2 (de) 2010-06-17 2013-04-24 The United States Of America As Represented By The Secretary, National Institutes Of Health Zusammensetzungen und verfahren zur behandlung von entzündungserkrankungen
CN107090456B (zh) 2010-08-02 2022-01-18 瑟纳治疗公司 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制
GB2482709A (en) * 2010-08-11 2012-02-15 Envirogene Ltd Tracer
JP6106085B2 (ja) 2010-08-24 2017-03-29 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 内部非核酸スペーサーを含む一本鎖ＲＮＡｉ剤
WO2012027467A1 (en) 2010-08-26 2012-03-01 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012027675A2 (en) 2010-08-26 2012-03-01 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
US8642087B1 (en) 2010-11-05 2014-02-04 University Of Kentucky Research Foundation Compounds and methods for reducing oxidative stress
EP2691443B1 (de) 2011-03-28 2021-02-17 Massachusetts Institute of Technology Konjugierte lipomers und ihre verwendung
ES2582324T3 (es) 2011-05-27 2016-09-12 20Med Therapeutics B.V. Nanogeles
JP6184945B2 (ja) 2011-06-08 2017-08-23 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ｍＲＮＡ送達のための脂質ナノ粒子組成物および方法
WO2013040552A2 (en) 2011-09-16 2013-03-21 Georgia Health Sciences University Methods of promoting immune tolerance
AU2012328570B2 (en) 2011-10-27 2017-08-31 Massachusetts Institute Of Technology Amino acid derivatives functionalized on the n-terminus capable of forming drug encapsulating microspheres and uses thereof
CA2856116A1 (en) 2011-11-17 2013-05-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Therapeutic rna switches compositions and methods of use
EA201491185A1 (ru) 2011-12-16 2015-05-29 Массачусетс Инститьют Оф Текнолоджи Полимеры альфа-аминоамидинов и их применение
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
BR112014021068A8 (pt) 2012-02-21 2018-01-23 Centre National De La Recherce Scient inibidor de uma interação entre fosfatidilserina e um receptor tim, composição farmacêutica e uso de um inibidor
US20160015808A1 (en) 2012-02-21 2016-01-21 Institut National De La Sante Et De La Recherche Medicale (Inserm) Tam receptors as virus entry cofactors
US10278927B2 (en) 2012-04-23 2019-05-07 Massachusetts Institute Of Technology Stable layer-by-layer coated particles
EP3536787A1 (de) 2012-06-08 2019-09-11 Translate Bio, Inc. Nukleaseresistente polynukleotide und verwendungen davon
US20130337067A1 (en) 2012-06-15 2013-12-19 The Royal Institution For The Advancement Of Learning/Mcgill University Non-viral nanoparticle-based delivery system
CN104736563A (zh) 2012-07-27 2015-06-24 国家健康与医学研究院 Cd147作为受体用于脑膜炎球菌至血管内皮的菌毛介导的粘附
CA2884870C (en) 2012-08-13 2022-03-29 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
US9687569B2 (en) * 2012-08-16 2017-06-27 University Of Washington Through Its Center For Commercialization Theranostic nanoparticle and methods for making and using the nanoparticle
KR101445265B1 (ko) * 2012-09-18 2014-09-30 포항공과대학교 산학협력단 히알루론산-핵산 접합체 및 이를 포함하는 핵산 전달용 조성물
WO2014134029A1 (en) 2013-02-26 2014-09-04 Massachusetts Institute Of Technology Nucleic acid particles, methods and use thereof
GB201304245D0 (en) * 2013-03-08 2013-04-24 Inst Quimic De Sarria Chemical compounds
EA037922B1 (ru) 2013-03-14 2021-06-07 Шир Хьюман Дженетик Терапис, Инк. мРНК CFTR И КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ МУКОВИСЦИДОЗА У МЛЕКОПИТАЮЩЕГО
EP2970955B1 (de) 2013-03-14 2018-11-14 Translate Bio, Inc. Verfahren zur reinigung von messenger-rna
US9463244B2 (en) 2013-03-15 2016-10-11 Massachusetts Institute Of Technology Compositions and methods for nucleic acid delivery
US9315472B2 (en) 2013-05-01 2016-04-19 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
CA2928186A1 (en) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Mrna therapy for phenylketonuria
EP3060257B1 (de) 2013-10-22 2021-02-24 Translate Bio, Inc. Lipidzusammensetzungen zur verabreichung von mrna
ES2954366T3 (es) 2013-10-22 2023-11-21 Translate Bio Inc Terapia de ácido ribonucleico mensajero para la deficiencia de argininosuccinato sintetasa
CA2924013A1 (en) * 2013-11-05 2015-05-14 Clontech Laboratories, Inc. Dry transfection compositions and methods for making and using the same
ES2750661T3 (es) 2014-04-25 2020-03-26 Translate Bio Inc Métodos para la purificación de ARN mensajero
AU2015253100B2 (en) 2014-04-30 2018-01-18 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
JP6557722B2 (ja) 2014-05-30 2019-08-07 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 核酸の送達のための生分解性脂質
WO2015191693A2 (en) 2014-06-10 2015-12-17 Massachusetts Institute Of Technology Method for gene editing
ES2964588T3 (es) 2014-06-24 2024-04-08 Translate Bio Inc Composiciones enriquecidas estereoquímicamente para la administración de ácidos nucleicos
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
US10736966B2 (en) 2014-08-12 2020-08-11 Massachusetts Institute Of Technology Brush-poly (glycoamidoamine)-lipids and uses thereof
CA2957721C (en) 2014-08-13 2021-04-13 The Johns Hopkins University Selective dendrimer delivery to brain tumors
EP2995318B1 (de) * 2014-09-09 2022-12-07 Istanbul Universitesi Rektorlugu Synthese von nanopartikulären genträgersystemen auf basis von poly(beta-aminoestern)
US10415037B2 (en) 2014-10-02 2019-09-17 Arbutus Biopharma Corporation Compositions and methods for silencing hepatitis B virus gene expression
WO2016094342A1 (en) 2014-12-08 2016-06-16 The Board Of Regents Of The University Of Texas System Lipocationic polymers and uses thereof
US20180245074A1 (en) 2015-06-04 2018-08-30 Protiva Biotherapeutics, Inc. Treating hepatitis b virus infection using crispr
PL3310764T3 (pl) 2015-06-19 2023-11-06 Massachusetts Institute Of Technology Podstawione alkenylem 2,5-piperazynodiony i ich zastosowanie w kompozycjach do dostarczania środka do osobnika lub komórki
US20180208932A1 (en) 2015-07-29 2018-07-26 Arbutus Biopharma Corporation Compositions and methods for silencing hepatitis b virus gene expression
CN105131182B (zh) * 2015-09-06 2017-07-21 山东大学 普朗尼克‑聚(β‑氨基酯)聚合物及其合成和应用方法
GB201519375D0 (en) * 2015-11-03 2015-12-16 Univ Cardiff Photodynamic therapy complex
US10413616B2 (en) 2015-12-23 2019-09-17 Viking Scientific, Inc. Hydrogel prodrug for treatment
US10188749B2 (en) * 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
WO2017181110A1 (en) * 2016-04-14 2017-10-19 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
EP3565535A4 (de) 2017-01-05 2020-12-30 Fred Hutchinson Cancer Research Center Systeme und verfahren zur verbesserung der impfstoffwirksamkeit
MX2019010155A (es) 2017-02-27 2020-12-10 Translate Bio Inc Arnm de cftr optimizado por codón novedoso.
IL270631B2 (en) 2017-05-16 2024-03-01 Translate Bio Inc Treatment of cystic fibrosis through the administration of mRNA with an optimal codon encoding ctfr
WO2019075056A1 (en) * 2017-10-10 2019-04-18 The Johns Hopkins University BIODEGRADABLE BIOMIMETIC PARTICLES
WO2019084229A1 (en) 2017-10-27 2019-05-02 Massachusetts Institute Of Technology POLY (BETA-AMINO ESTERS) AND USES THEREOF
WO2019089567A1 (en) 2017-10-30 2019-05-09 Massachusetts Institute Of Technology Layer-by-layer nanoparticles for cytokine therapy in cancer treatment
WO2019101882A1 (en) 2017-11-23 2019-05-31 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating dengue virus infection
CN109954144B (zh) * 2017-12-14 2022-07-08 复旦大学 基于改性聚β-氨基酯材料的双级pH响应纳米粒及其制备方法
CN112930396B (zh) 2018-08-24 2024-05-24 川斯勒佰尔公司 用于纯化信使rna的方法
BR112021003897A2 (pt) 2018-08-30 2021-05-25 Tenaya Therapeutics, Inc. reprogramação de células cardíacas com miocarina e asci1
AU2019366996A1 (en) 2018-10-26 2021-05-27 Massachusetts Institute Of Technology Polymer-lipids and compositions
EP3714913A1 (de) * 2019-03-29 2020-09-30 Picosun Oy Farbcodierung
US20220202951A1 (en) * 2019-05-14 2022-06-30 Universidade De Coimbra Light-triggerable nanoparticle library of formulations for the controlled release of rnas
JP2022532256A (ja) 2019-05-16 2022-07-13 ジェム イノヴ 生分解性マイクロカプセルの調製方法及びこの方法で得たマイクロカプセル
WO2021002984A1 (en) 2019-05-30 2021-01-07 Massachusetts Institute Of Technology Peptide nucleic acid functionalized hydrogel microneedles for sampling and detection of interstitial fluid nucleic acids
EP3997226A1 (de) 2019-07-11 2022-05-18 Tenaya Therapeutics, Inc. Umprogrammierung von herzzellen mit mikrornas und anderen faktoren
IL293606A (en) 2019-12-04 2022-08-01 Ashvattha Therapeutics Inc Dendrimer preparations and methods of administering a drug to the eye
CN111568856B (zh) * 2020-06-24 2021-07-06 珠海舒桐医疗科技有限公司 一种阴道凝胶制剂及其制备方法
US11945946B2 (en) 2020-09-14 2024-04-02 Encapsys, Llc Polyurea and poly(beta-amino ester) capsules with enhanced degradability
CN115010991A (zh) * 2020-11-11 2022-09-06 绍兴瑞康生物科技有限公司 空间位阻可调型弱碱光稳定剂及其制备方法和应用
US20220153901A1 (en) * 2020-11-19 2022-05-19 Encapsys,LLC Poly Acrylate and Poly(Beta-Amino Ester) Capsules with Enhanced Degradability
EP4000725A1 (de) 2020-11-19 2022-05-25 The Procter & Gamble Company Verbraucherprodukt mit polyacrylate- und poly(beta-aminoester)-abgabekapseln mit verbesserter abbaubarkeit
CN112851934B (zh) * 2020-12-29 2022-05-10 浙江大学杭州国际科创中心 一种含N-氧化三级胺基团的聚(β-氨基酯)及其制备方法和应用
WO2022192176A1 (en) 2021-03-09 2022-09-15 Massachusetts Institute Of Technology Branched poly(-amino esters) for the delivery of nucleic acids
WO2023059806A1 (en) 2021-10-06 2023-04-13 Massachusetts Institute Of Technology Lipid nanoparticles for drug delivery to microglia in the brain
CN113929904B (zh) * 2021-10-14 2022-10-25 西安交通大学 一类功能性单链环状聚(β-氨基酯)及其制备方法和基因递送药物应用
AU2022371414A1 (en) 2021-10-20 2024-05-02 University Of Copenhagen Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss
EP4183884A1 (de) * 2021-11-19 2023-05-24 Branca Bunus Limited Verfahren zur herstellung einer fraktion eines ausgangspolymervektors zur gentherapie
WO2023102024A1 (en) * 2021-11-30 2023-06-08 Massachusetts Institute Of Technology POLY(β-AMINO ESTER) MICROPARTICLES FOR MICRONUTRIENT FORTIFICATION
KR102662360B1 (ko) * 2022-11-01 2024-06-17 주식회사 옴니아메드 이온화 모이어티를 갖는 중합체 기반의 핵산 분자 전달체

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1668502A1 (de) * 1967-11-07 1971-09-02 Nii Monomerow Dlja Sintetitsch Verfahren zur Herstellung von Akryl-und Methakrylestern
US4224365A (en) * 1978-05-15 1980-09-23 Glass Containers Corporation Method of coating glass containers and product
US4348511A (en) * 1980-05-07 1982-09-07 Ciba-Geigy Corporation Process for the preparation of crosslinked, unsaturated polymers and the polymers thus obtained
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US5180424A (en) 1991-10-07 1993-01-19 Westvaco Corporation Michael addition aminopolyester resins as dilution extenders for zinc-containing metal resinate inks
US5364634A (en) * 1991-11-08 1994-11-15 Southwest Research Institute Controlled-release PH sensitive capsule and adhesive system and method
KR100266912B1 (ko) * 1992-02-28 2000-12-01 파라비 레이 조직접촉물질이며 방출조절운반체인 광중합성 생분해성 하이드로겔
US5573934A (en) * 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
CA2156288C (en) * 1993-02-19 2005-10-18 Junichi Yano Glycerol derivative, device and pharmaceutical composition
US5770637A (en) * 1996-05-01 1998-06-23 Johnson & Johnson Vision Products, Inc. Anti-bacterial, UV absorbable, tinted, metal-chelating polymers
US5904927A (en) * 1997-03-14 1999-05-18 Northeastern University Drug delivery using pH-sensitive semi-interpenetrating network hydrogels
US5962520A (en) * 1998-04-02 1999-10-05 The University Of Akron Hydrolytically unstable, biocompatible polymer
DE19822602A1 (de) * 1998-05-20 1999-11-25 Goldschmidt Ag Th Verfahren zur Herstellung von Polyaminosäureestern durch Veresterung von sauren Polyaminosäuren oder Umesterung von Polyaminosäureestern
US6998115B2 (en) * 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof

Also Published As

Publication number Publication date
JP2010180412A (ja) 2010-08-19
US20040071654A1 (en) 2004-04-15
WO2004106411A3 (en) 2005-01-20
JP4740864B2 (ja) 2011-08-03
CA2527722A1 (en) 2004-12-09
DE602004007518T2 (de) 2008-03-20
ES2290737T3 (es) 2008-02-16
EP1903068B1 (de) 2010-07-28
DE602004028418D1 (de) 2010-09-09
ATE475685T1 (de) 2010-08-15
EP1639029A2 (de) 2006-03-29
DE602004007518D1 (de) 2007-08-23
ES2350055T3 (es) 2011-01-17
CA2527722C (en) 2013-04-16
WO2004106411A2 (en) 2004-12-09
EP1903068A1 (de) 2008-03-26
JP5558154B2 (ja) 2014-07-23
EP1639029B1 (de) 2007-07-11
JP2007504353A (ja) 2007-03-01
PT1639029E (pt) 2007-09-26
US7427394B2 (en) 2008-09-23
JP2014129536A (ja) 2014-07-10

Similar Documents

Publication Publication Date Title
ATE366769T1 (de) Biologisch abbaubare poly(beta-aminoester) und anwendungen davon
WO2002031025A3 (en) Biodegradable poly(beta-amino esters) and uses thereof
Shi et al. Polyhedral oligomeric silsesquioxanes (POSS)-based hybrid soft gels: Molecular design, material advantages, and emerging applications
Akhtar et al. Methods of synthesis of hydrogels… A review
WO2006138380A3 (en) Amine-containing lipids and uses thereof
DE602006007177D1 (de) Polyglutamat-aminosäure-konjugate und verfahren
DE60135486D1 (de) Zusammensetzungen zur verzögerten abgabe von hydrophoben arzneimitteln und verfahren zu ihrer herstellung
WO2007133807A3 (en) Polymers for functional particles
UA95225C2 (ru) Модифицированный полимером фактор viii для лечения гемофилии, способ его получения
DE602005027461D1 (de) Konjugate zur zuführung an knochen und verfahren zu deren verwendung beim hinführen von proteinen zum knochen
DE60033969D1 (de) Hydrolytisch abbaubare carbamatderivate von polyethylenglykol
WO2013090861A8 (en) Alpha-aminoamidine polymers and uses thereof
WO2006081210A3 (en) Medical device with drug release regions containing pseudo - block copolymers
WO2007127440A3 (en) Heterofunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof
MX353900B (es) Lipidoides de aminoalcohol y usos de los mismos.
ATE214918T1 (de) Polymere lamellare substratpartikel zur arzneistoffverabreichung
DE60227435D1 (de) Polymerisches fluoreszentes Material, Verfahren zu seiner Herstellung und lumineszentes Polymergerät
SE0202619D0 (sv) New Polymers and Applications
ATE459345T1 (de) Wirkstoffpartikelhaltiges transdermales therapeutisches system mit erhöhtem wirkstofffluss
WO2001068052A3 (en) Phosphate based biodegradable polymers
WO2017141204A3 (en) Biguanide grafted / modified biopolymers as drug delivery vehicles
DE60335719D1 (de) Materialien mit bioadhäsiven und biologisch abbaubaren komponenten
RU2012145811A (ru) Композиции и способы улучшенного удержания фармацевтической композиции на участке местного введения
DE602006004695D1 (de) Pharmazeutische Zubereitungsform von aliphatischen amin-Polymeren und Verfahren zu deren Herstellung
EA200600259A1 (ru) Реакционноспособные полимеры и сополимеры на основе n-(2-гидроксипропил)метакриламида, способ их получения и их применение для синтеза полимерных лекарственных средств, для модификации биологически активных белков и получения систем доставки генов

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties